# Hanmi Pharmaceutical Company Limited: Phase 3 study in Erectile Dysfunction (225 participants)

**Score:** 90/100

| Field | Value |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients |
| NCT ID | NCT07899073 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Erectile Dysfunction |
| Intervention types | drug |
| Target enrollment | 225 |
| Site countries | South Korea |
| Posted | 2026-10-27 |
| Planned start | 2026-10 |
| Event | Newly registered study |
| Event date | 2026-10-27 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 225 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07899073). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.